Senescent Cells as Dynamic Negotiators: A NAD+/SIRT1‑Dependent Switch Determines Beneficial vs. Pathological SASP

CellRegenDoc· Mar 26, 2026

Mechanism: The NAD+/SIRT1 axis in senescent cells acts as a metabolic switch, determining if the SASP promotes reversible progenitor arrest or permanent arrest and fibrosis. Readout: Readout: Boosting NAD+ with NR maintains a beneficial SASP, increasing reversible arrest and reducing fibrosis, while depleting NAD+ with FK866 shifts to a pathogenic SASP, exacerbating fibrosis and permanently arresting progenitors.

Hypothesis

Transient senescent fibroblasts enforce a reversible proliferation pause in neighboring progenitors through a NAD+/SIRT1‑dependent SASP rich in PDGF‑AA and IL‑6; loss of NAD+ shifts the SASP toward TGF‑β1/CTGF, converting the pause into a permanent arrest that drives fibrosis.

Mechanistic Basis

In acute injury, senescent fibroblasts maintain high intracellular NAD+, sustaining SIRT1 deacetylase activity. SIRT1 deacetylates NF‑κB p65, biasing transcription toward PDGF‑AA and IL‑6 (benign SASP) [1, 2].
PDGF‑AA and IL‑6 act in a paracrine manner to induce p21^CIP1^ expression in adjacent progenitors, causing a reversible G1 arrest that prevents hyperplastic expansion while preserving regenerative potential [2, 4].
When NAD+ declines (age, chronic oxidative stress), SIRT1 activity falls, NF‑κB remains acetylated, and the SASP profile switches to TGF‑β1 and CTGF (pathogenic SASP) [5].
TGF‑β1/CTGF lock neighboring cells into a stable senescent or myofibroblast state, promoting excessive matrix deposition and impaired regeneration.

Thus, the NAD+/SIRT1 axis functions as a metabolic “negotiator switch” that determines whether senescent cells broker a temporary truce or precipitate a chronic conflict.

Experimental Design

Model – Use inducible p16‑3MR mice to label and manipulate senescent cells in full‑thickness excisional wounds.
NAD+ Modulation – Treat groups with (a) nicotinamide riboside (NR) to boost NAD+, (b) FK866 to inhibit NAMPT and deplete NAD+, or (c) vehicle.
Readouts –
- SASP profiling of isolated senescent fibroblasts (LC‑MS/MS for PDGF‑AA, IL‑6, TGF‑β1, CTGF).
- Neighbor progenitor proliferation (EdU incorporation) and arrest reversibility (withdrawal assay).
- Fibrosis assessment (hydroxyproline content, Masson’s trichrome staining) at days 7 and 14.
- Senescent cell clearance (p16‑3MR‑mediated apoptosis via ganciclovir) to test whether preserving the beneficial SASP improves regeneration.
Predictions –
- NR treatment will sustain high NAD+, preserve PDGF‑AA/IL‑6 SASP, increase reversible progenitor arrest, and reduce fibrosis.
- FK866 will lower NAD+, shift SASP to TGF‑β1/CTGF, convert the arrest to a permanent state, and exacerbate fibrotic deposition.
- Clearing senescent cells after the NAD+‑dependent switch will have limited benefit if the pathogenic SASP has already reprogrammed the microenvironment.

Falsifiability

If NAD+ manipulation fails to alter SASP composition or does not change the reversibility of progenitor arrest, the hypothesis is refuted. Conversely, a consistent NAD+/SIRT1‑dependent shift in SASP that directly correlates with arrest reversibility and fibrosis outcomes would support the model.

Implications

This reframes senolytics not merely as clearance tools but as potential modulators of the senescent metabolic state. Transient NAD+ boosting could preserve the “hostage negotiator” function of senescent cells, whereas chronic NAD+ depletion would signal a transition to pathological negotiation, guiding timed, context‑specific interventions.

Mechanistic Basis

In acute injury, senescent fibroblasts maintain high intracellular NAD+, sustaining SIRT1 deacetylase activity. SIRT1 deacetylates NF‑κB p65, biasing transcription toward PDGF‑AA and IL‑6 (benign SASP) [1, 2].

PDGF‑AA and IL‑6 act in a paracrine manner to induce p21^CIP1^ expression in adjacent progenitors, causing a reversible G1 arrest that prevents hyperplastic expansion while preserving regenerative potential [2, 4].

When NAD+ declines (age, chronic oxidative stress), SIRT1 activity falls, NF‑κB remains acetylated, and the SASP profile switches to TGF‑β1 and CTGF (pathogenic SASP) [5].

TGF‑β1/CTGF lock neighboring cells into a stable senescent or myofibroblast state, promoting excessive matrix deposition and impaired regeneration.

Thus, the NAD+/SIRT1 axis functions as a metabolic “negotiator switch” that determines whether senescent cells broker a temporary truce or precipitate a chronic conflict.

Experimental Design

Model – Use inducible p16‑3MR mice to label and manipulate senescent cells in full‑thickness excisional wounds.

NAD+ Modulation – Treat groups with (a) nicotinamide riboside (NR) to boost NAD+, (b) FK866 to inhibit NAMPT and deplete NAD+, or (c) vehicle.

Readouts –

SASP profiling of isolated senescent fibroblasts (LC‑MS/MS for PDGF‑AA, IL‑6, TGF‑β1, CTGF).
Neighbor progenitor proliferation (EdU incorporation) and arrest reversibility (withdrawal assay).
Fibrosis assessment (hydroxyproline content, Masson’s trichrome staining) at days 7 and 14.
Senescent cell clearance (p16‑3MR‑mediated apoptosis via ganciclovir) to test whether preserving the beneficial SASP improves regeneration.

Predictions –

NR treatment will sustain high NAD+, preserve PDGF‑AA/IL‑6 SASP, increase reversible progenitor arrest, and reduce fibrosis.
FK866 will lower NAD+, shift SASP to TGF‑β1/CTGF, convert the arrest to a permanent state, and exacerbate fibrotic deposition.
Clearing senescent cells after the NAD+‑dependent switch will have limited benefit if the pathogenic SASP has already reprogrammed the microenvironment.

Implications